COMMUNIQUÉS West-GlobeNewswire

-
Shire plc : Rule 2.9 announcement
27/06/2018 -
Dividend payment ex-date of AS “Latvijas Jūras medicīnas centrs”
27/06/2018 -
ThromboGenics Plans Name Change to "Oxurion"
27/06/2018 -
MDxHealth's SelectMDx Test Successfully Stratifies Men
27/06/2018 -
Le test SelectMDx de MDxHealth classe avec succès les hommes
27/06/2018 -
Biocartis Group NV: Study Reviewing 2,500 Performed Idylla(TM) Tests Shows Generation of Valid Results in 98.1% of Cases and Outperformance over Reference Methods
27/06/2018 -
iTeos Therapeutics Expands Board of Directors with the Appointment of David Hallal as Chairman and Tim Van Hauwermeiren as an Independent Director
27/06/2018 -
Assure Holdings Corp. Announces Update
27/06/2018 -
Peer-reviewed Neurology Publication on Medibio Science
27/06/2018 -
Image Following Treatment with 177Lu-PSMA-617 Selected by Society of Nuclear Medicine and Molecular Imaging as Image of the Year
27/06/2018 -
Neon Therapeutics Announces Pricing of Initial Public Offering
27/06/2018 -
Pain Therapeutics Announces Results of FDA Advisory Committee Meeting for REMOXY ER
26/06/2018 -
Dentsply Sirona Declares Quarterly Cash Dividend
26/06/2018 -
VistaGen Therapeutics Reports Fiscal Year 2018 Financial Results and Provides Year-to-Date Highlights
26/06/2018 -
Apellis Pharmaceuticals Announces First Patient Enrolled in Phase 3 APL-2 Head-to-Head Study in Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Soliris™
26/06/2018 -
Globus Medical Announces ExcelsiusGPS® Milestone: 3,000 screws implanted
26/06/2018 -
Xeris Pharmaceuticals Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
26/06/2018 -
Medigus Enters Orthopedic Market with New Development and Manufacturing Agreement for Integrated Visualization Device with A.M. Surgical Inc.
26/06/2018 -
Amicus Therapeutics Announces European Regulatory and Clinical Updates for AT-GAA in Pompe Disease
26/06/2018
Pages